Tied with Cabenuva for second place was Amgen’s Lumakras, which was approved in 2021 for non-small cell lung cancer and boasted impressive therapeutic and R&D scores, but fell behind both ...

Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...

With a sumptuous 240 Hz OLED display, a supremely slim and well-built chassis, and gaming performance to be proud of, I was absolutely smitten. You may like Time for me to tap the Asus G14 sign ...

Overall survival was statistically significantly improved in adults treated with tislelizumab/chemotherapy compared with placebo/chemotherapy. The Food and Drug ...

Issued on behalf of Oncolytics Biotech Inc. At the ASCO GI event, Oncolytics shared that in relapsed anal cancer, 4 out of 12 evaluable patients achieved a partial response for a response rate of ...

Like Jurassic Park, Matlock and Star Wars, the new Toyota Urban Cruiser is a reboot of something that’s come before. Where the previous Urban Cruiser was a fairly underwhelming SUV, however ...

Like Jurassic Park, Matlock and Star Wars, the new Toyota Urban Cruiser is a reboot of something that’s come before. Where the previous Urban Cruiser was a fairly underwhelming SUV, however ...

The letter, more than 240 years old, is written on both sides of a single sheet of paper roughly 8 by 12 inches. It is stained and discolored in many places and has what looks like a grimy ...

In January and February of this year, the US Food and Drug Administration granted approvals for Adcetris (brentuximab vedotin), Lumakras (sotorasib), Grafapex (treosulfan), Enhertu (fam ...